Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments.
Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing 60 billion USD U.S. cancer screening and precision oncology. Abbott Park, Illinois, and Madison, Wisconsin, Nov. 20, 2025 /PRNewswire/ — Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving millions more people. Under the terms of the agreement, Exact Sciences shareholders will receive 105 USD per common share, representing a total equity value of approximately 21 billion USD. Together, the companies will accelerate innovation, expand access to life-changing diagnostics, and help more people detect and manage cancer at its earliest, most treatable stages. Exact Sciences focuses on the early detection of cancer and supporting personalized treatments. Exact Sciences' comprehensive product offerings support patients and their healthcare providers before, during and after a cancer diagnosis. The company is a leader in cancer screening, precision oncology and genetic testing, helping to detect cancer earlier, guide treatment decisions and monitor for recurrence.
Exact Sciences focuses on the early detection of cancer and supporting personalized treatments. The company is a leader in cancer screening, precision oncology and genetic testing, helping to detect cancer earlier, guide treatment decisions and monitor for recurrence.
Авторское резюме: Abbott стремится расширить портфель за счет приобретения Exact Sciences, чтобы ускорить инновации и увеличить доступ к передовым диагностическим технологиям в раке, при этом сохранив фокус на раннем обнаружении и индивидуализированном лечении.